In this context, if this is true, then TASK-1 inhibitors such as KU124 could potentially serve as adjuvant therapies, enhancing the cytotoxic effects of immune therapies and improving treatment outcomes in resistant cancer phenotypes. The gene discussed is KCNK3; the disease is cancer.